Haemato AG

Haemato AG maintains a strong liquidity position with a current ratio of 2.59 and cash and equivalents of 23.81 million EUR, indicating the company has sufficient short-term assets to cover its liabilities. The company's debt-to-equity ratio is 0.04, suggesting a conservative capital structure with minimal reliance on debt financing. The low liquidity risk is further supported by the absence of immediate filing-based liquidity flags. In terms of profitability, Haemato AG reports a return on equity (ROE) of 5.57% and a return on assets (ROA) of 4.64%, which are below the typical thresholds for high-performing pharmaceutical firms. The company's operating income of 8.30 million EUR and net income of 8.19 million EUR reflect modest profitability relative to its revenue of 248.14 million EUR. These figures suggest that the company is generating returns, but not at a level that would be considered exceptional within the industry. Haemato AG's revenue is distributed across two segments: specialty pharma and lifestyle and aesthetics. The specialty pharma segment is the core of the company's operations, focusing on HIV, oncology, and other chronic diseases. The lifestyle and aesthetics segment, a newer addition through the subsidiary M1 Aesthetics GmbH, is into marketing products for aesthetic surgery and cosmetic dermatology. The company's geographic exposure is primarily within Germany, with no significant international revenue disclosed. The company's growth trajectory is modest, with no significant revenue growth reported in the latest financial data. The operating cash flow of 19.73 million EUR and free cash flow of 2.72 million EUR indicate that the company is generating positive cash from operations, but the capital expenditure of -1.09 million EUR suggests that the company is not heavily investing in new projects or expansion. The absence of immediate dilution flags and the low dilution risk suggest that the company is not expected to issue additional shares in the near term. The risk assessment for Haemato AG indicates a low liquidity risk and a low dilution risk. The company's financial structure is stable, with no immediate filing-based liquidity or dilution flags detected. The low risk profile is further supported by the conservative capital structure and the absence of significant debt obligations. The company's risk score is not explicitly provided, but the low risk indicators suggest a relatively stable financial position. Recent events and filings for Haemato AG do not indicate any significant changes or risks. The company's financial performance and risk profile remain stable, with no immediate concerns for liquidity or dilution. The company's operations and financial structure are consistent with its current business model and strategic direction.